Iron chelating agents in clinical practice
- 1 April 1999
- journal article
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 184 (1) , 291-310
- https://doi.org/10.1016/s0010-8545(99)00056-9
Abstract
No abstract availableThis publication has 107 references indexed in Scilit:
- Cardioprotective Effect of DesferrioxamineActa Haematologica, 1996
- Transferrin-receptor-independent but iron-dependent proliferation of variant Chinese hamster ovary cellsExperimental Cell Research, 1992
- Vision and hearing during deferoxamine therapyThe Journal of Pediatrics, 1990
- Deferoxamine-induced growth retardation in patients with thalassemia majorThe Journal of Pediatrics, 1988
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- The study of iron mobilisation from transferrin using α-ketohydroxy heteroaromatic chelatorsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1986
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985
- Control of homozygous β-thalassemia by carrier screening and antenatal diagnosis in SardiniansClinical Genetics, 1984
- Mobilization of iron from reticulocytesFEBS Letters, 1979
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977